TYGRIS - ROW
What it found
A paper reports the results; we have not read it yet. See Papers below.
What it measured
Main measures
Number of participants with serious infections, malignancies, and other serious adverse events (SAEs)
5 Years
Safety
Who could take part
MS (type not specified)
Key Inclusion Criteria: * All Multiple Sclerosis (MS) participants in Rest of World (ROW) who are prescribed and receiving TYSABRI in normal clinical practice at centers that are taking part in the study are eligible to participate in TYGRIS - ROW. Participants must have received at least 1 and not more than 3 infusions of TYSABRI. NOTE: Other protocol defined Inclusion/Exclusion criteria may apply.
As registered. Criteria can change, so ask the trial team or your neurologist.
About this trial
In the sponsor's words
The primary objective of this study is to determine the incidence and pattern of serious infections, malignancies, and other serious adverse events (SAEs) in participants with multiple sclerosis (MS) treated with TYSABRI (natalizumab).
Papers
Loading reviews and guidelines…
Linked trials
Referred to by
Safety and Efficacy in Pediatric MS Patients Prescribed T…Completed
Links found where a registry record names another trial's registry number.
History
Started
Sept 2006
Main results due
Nov 2014
Finished
Nov 2014
Assembled by software from public sources and not checked by people. Each record links to its source. Report an error